168 results on '"Coste‐Burel, Marianne"'
Search Results
2. Epidemiological and clinical insights into the enterovirus D68 upsurge in Europe 2021/22 and the emergence of novel B3-derived lineages, ENPEN multicentre study
3. The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics
4. Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France
5. Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
6. Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
7. Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
8. Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation
9. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
10. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
11. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1–6 by sequencing the NS3 protease region using a single optimized sensitive method
12. Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients
13. SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
14. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
15. Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy
16. Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
17. Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
18. Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
19. New introductions of enterovirus 71 subgenogroup C4 strains, France, 2012
20. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
21. Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
22. Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
23. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France
24. Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
25. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 vaccine
26. Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France
27. Viral DNA contamination is responsible for Epstein–Barr virus detection in cytotoxic T lymphocytes stimulated in vitro with Epstein–Barr virus B-lymphoblastoid cell line
28. Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination.
29. The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study
30. T cell repertoire and Epstein–Barr virus-specific T cell response in chronic active Epstein–Barr virus infection: A case study
31. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study
32. Evidence of recombination in natural populations of hepatitis A virus
33. Emergence of enterovirus D68 clade D1, France, August to November 2018
34. Nosocomial Acinetobacter baumannii Infections: Microbiological and Clinical Epidemiology
35. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant.
36. Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy.
37. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study
38. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity
39. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
40. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity
41. Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort
42. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT)
43. Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT)
44. Features of Epstein Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) unrelated umbilical cord blood transplantation (UCBT)
45. Chronic Infection, a Neglected Cause Of Development Of Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Myeloma
46. Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins
47. A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT)
48. Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France
49. Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT)
50. Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.